Cogent Biosciences (COGT) Stock Forecast & Price Target

Compare

695 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

COGT Analyst Ratings

Strong Buy

9 Buy

2 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Cogent

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

COGT Stock 12 Month Forecast

Average Price Target

$43.11

▲(2.38% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Cogent Biosciences in the last 3 months. The average price target is $43.11 with a high forecast of $53.00 and a low forecast of $30.00. The average price target represents a 2.38% change from the last price of $42.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","29":"$29","54":"$54","16.5":"$16.5","41.5":"$41.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$53.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.111111111111114,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$43.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,16.5,29,41.5,54],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.76,40.778461538461535,41.79692307692307,42.815384615384616,43.83384615384615,44.85230769230769,45.87076923076923,46.889230769230764,47.90769230769231,48.926153846153845,49.94461538461538,50.963076923076926,51.98153846153846,{"y":53,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.76,40.01777777777777,40.275555555555556,40.53333333333333,40.791111111111114,41.04888888888889,41.306666666666665,41.56444444444445,41.82222222222222,42.08,42.33777777777778,42.595555555555556,42.85333333333334,{"y":43.111111111111114,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.76,39.00923076923077,38.25846153846154,37.50769230769231,36.75692307692307,36.00615384615384,35.255384615384614,34.504615384615384,33.753846153846155,33.003076923076925,32.252307692307696,31.50153846153846,30.75076923076923,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.47,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.61,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.76,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$53.00

Average Price Target$43.11

Lowest Price Target$30.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Laura Prendergast

Stifel Nicolaus

$40

Buy

-5.01%

Downside

Reiterated

12/15/25

Analysts' Top Healthcare Picks: Cogent Biosciences (COGT), Novan (NOVN)

Ami Fadia

Needham

Hold

―

Reiterated

12/08/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immatics (NASDAQ: IMTX), Incyte (NASDAQ: INCY) and Cogent Biosciences (NASDAQ: COGT)

Michael Schmidt

Guggenheim

$20→$45

Buy

6.86%

Upside

Reiterated

12/08/25

Guggenheim Sticks to Their Buy Rating for Cogent Biosciences (COGT)

Clara Dong

Jefferies

$45→$48

Buy

13.99%

Upside

Reiterated

12/08/25

Cogent Biosciences (COGT) Gets a Buy from Jefferies

Anupam Rama

J.P. Morgan

Buy

―

Reiterated

12/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Sam Slutsky

LifeSci Capital

$32→$53

Buy

25.86%

Upside

Reiterated

11/15/25

Cogent Biosciences (COGT) Gets a Buy from LifeSci Capital

Robert Burns

H.C. Wainwright

$21→$50

Buy

18.74%

Upside

Reiterated

11/13/25

H.C. Wainwright Reaffirms Their Buy Rating on Cogent Biosciences (COGT)

Colleen M. Kusy

Robert W. Baird

$14→$34

Hold

-19.26%

Downside

Reiterated

11/11/25

Cogent Biosciences price target raised to $34 from $14 at BairdCogent Biosciences price target raised to $34 from $14 at Baird

Andrew Berens

Leerink Partners

$18→$50

Buy

18.74%

Upside

Assigned

11/10/25

Cogent Biosciences price target raised to $50 from $18 at LeerinkCogent Biosciences price target raised to $50 from $18 at Leerink

David Nierengarten

Wedbush

$13→$38

Buy

-9.76%

Downside

Upgraded

11/10/25

Cogent Biosciences upgraded to Outperform from Neutral at WedbushCogent Biosciences upgraded to Outperform from Neutral at Wedbush

Christopher Raymond

Raymond James

$30

Buy

-28.76%

Downside

Reiterated

09/22/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

David Lebowitz

Citi

$22

Buy

-47.76%

Downside

Reiterated

09/04/25

Optimistic Buy Rating for Cogent Biosciences Driven by Bezuclastinib's Potential and Expected 68.2% Share Price Return

Louise Chen

Scotiabank

$17

Buy

-59.63%

Downside

Reiterated

08/06/25

Scotiabank Remains a Buy on Cogent Biosciences (COGT)

Allison Bratzel

Piper Sandler

$24

Buy

-43.01%

Downside

Reiterated

07/28/25

Cogent Biosciences (COGT) Receives a Buy from Piper Sandler

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Laura Prendergast

Stifel Nicolaus

$40

Buy

-5.01%

Downside

Reiterated

12/15/25

Analysts' Top Healthcare Picks: Cogent Biosciences (COGT), Novan (NOVN)

Ami Fadia

Needham

Hold

―

Reiterated

12/08/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immatics (NASDAQ: IMTX), Incyte (NASDAQ: INCY) and Cogent Biosciences (NASDAQ: COGT)

Michael Schmidt

Guggenheim

$20→$45

Buy

6.86%

Upside

Reiterated

12/08/25

Guggenheim Sticks to Their Buy Rating for Cogent Biosciences (COGT)

Clara Dong

Jefferies

$45→$48

Buy

13.99%

Upside

Reiterated

12/08/25

Cogent Biosciences (COGT) Gets a Buy from Jefferies

Anupam Rama

J.P. Morgan

Buy

―

Reiterated

12/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Sam Slutsky

LifeSci Capital

$32→$53

Buy

25.86%

Upside

Reiterated

11/15/25

Cogent Biosciences (COGT) Gets a Buy from LifeSci Capital

Robert Burns

H.C. Wainwright

$21→$50

Buy

18.74%

Upside

Reiterated

11/13/25

H.C. Wainwright Reaffirms Their Buy Rating on Cogent Biosciences (COGT)

Colleen M. Kusy

Robert W. Baird

$14→$34

Hold

-19.26%

Downside

Reiterated

11/11/25

Cogent Biosciences price target raised to $34 from $14 at BairdCogent Biosciences price target raised to $34 from $14 at Baird

Andrew Berens

Leerink Partners

$18→$50

Buy

18.74%

Upside

Assigned

11/10/25

Cogent Biosciences price target raised to $50 from $18 at LeerinkCogent Biosciences price target raised to $50 from $18 at Leerink

David Nierengarten

Wedbush

$13→$38

Buy

-9.76%

Downside

Upgraded

11/10/25

Cogent Biosciences upgraded to Outperform from Neutral at WedbushCogent Biosciences upgraded to Outperform from Neutral at Wedbush

Christopher Raymond

Raymond James

$30

Buy

-28.76%

Downside

Reiterated

09/22/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

David Lebowitz

Citi

$22

Buy

-47.76%

Downside

Reiterated

09/04/25

Optimistic Buy Rating for Cogent Biosciences Driven by Bezuclastinib's Potential and Expected 68.2% Share Price Return

Louise Chen

Scotiabank

$17

Buy

-59.63%

Downside

Reiterated

08/06/25

Scotiabank Remains a Buy on Cogent Biosciences (COGT)

Allison Bratzel

Piper Sandler

$24

Buy

-43.01%

Downside

Reiterated

07/28/25

Cogent Biosciences (COGT) Receives a Buy from Piper Sandler

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cogent Biosciences

1 Month

xxx

Success Rate

8/12 ratings generated profit

Average Return

+14.29%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +14.29% per trade.

3 Months

xxx

Success Rate

9/13 ratings generated profit

Average Return

+19.95%

assigned a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +19.95% per trade.

1 Year

Anupam RamaJ.P. Morgan

Success Rate

11/12 ratings generated profit

Average Return

+202.72%

reiterated a buy rating 9 days ago

Copying Anupam Rama's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +202.72% per trade.

2 Years

xxx

Success Rate

12/12 ratings generated profit

Average Return

+299.82%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +299.82% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

COGT Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, COGT has received 16 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. COGT average Analyst price target in the past 3 months is 43.11.

Each month's total comprises the sum of three months' worth of ratings.

COGT Financial Forecast

COGT Earnings Forecast

Next quarter’s earnings estimate for COGT is -$0.52 with a range of -$0.60 to -$0.41. The previous quarter’s EPS was -$0.50. COGT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year COGT has Performed in-line its overall industry.

COGT Sales Forecast

Next quarter’s sales forecast for COGT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. COGT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year COGT has Performed in-line its overall industry.

COGT Stock Forecast FAQ

What is COGT’s average 12-month price target, according to analysts?

Based on analyst ratings, Cogent Biosciences’s 12-month average price target is 43.11.

What is COGT’s upside potential, based on the analysts’ average price target?

Cogent Biosciences has 2.38% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is COGT a Buy, Sell or Hold?

Cogent Biosciences has a consensus rating of Strong Buy which is based on 9 buy ratings, 2 hold ratings and 0 sell ratings.

What is Cogent Biosciences’s price target?

The average price target for Cogent Biosciences is 43.11. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $53.00 ,the lowest forecast is $30.00. The average price target represents 2.38% Increase from the current price of $42.11.

What do analysts say about Cogent Biosciences?

Cogent Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of COGT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Cogent Biosciences (COGT) Stock Forecast & Price Target

COGT Analyst Ratings

COGT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cogent Biosciences

COGT Analyst Recommendation Trends

COGT Financial Forecast

COGT Earnings Forecast

COGT Sales Forecast

COGT Stock Forecast FAQ

Detailed List of Analyst Forecasts